Platelet-inhibitor therapy in cardiovascular disease. Effective defense against thromboembolism.
Platelet deposition can occur in areas of vascular damage and on prosthetic materials such as heart valves or grafts; mural thrombus formation, with eventual organization, progression to fatal occlusion, thrombolysis, or arterial embolization can follow. Use of antiplatelet drugs in patients undergoing certain cardiovascular surgical procedures or having rapid progression of atherosclerosis may reduce the thromboembolic risk.
Chesebro
J H
JH
Steele
P M
PM
Fuster
V
V
D000800:Angioplasty, Balloon; D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D001705:Bioprosthesis / Q000009:adverse effects; D001792:Blood Platelets / Q000187:drug effects; D003327:Coronary Disease / Q000188:drug therapy; D004176:Dipyridamole / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006083:Graft Occlusion, Vascular / Q000209:etiology / Q000517:prevention & control; D006350:Heart Valve Prosthesis / Q000009:adverse effects; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D011517:Prothrombin Time; D011897:Random Allocation; D013442:Sulfinpyrazone / Q000627:therapeutic use; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D013997:Time Factors; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D014859:Warfarin; D004176:Dipyridamole; D006493:Heparin; D001241:Aspirin; D013442:Sulfinpyrazone